. Author manuscript; available in PMC: 2020 Oct 1.

Published in final edited form as: J Subst Abuse Treat. 2019 Jul 24;105:37–43. doi: 10.1016/j.jsat.2019.07.010

Table A3.

Unadjusted logistic regressions

	(1) Tx Discontinuation	(2) Adverse Event	(3) Adverse Event
Tx Discontinuation			3.670^*** (0.202)
Dose = 4 mg or less	1.841^*** (0.101)	1.115 (0.0836)	0.949 (0.0723)
Days of supply = 1, 0-7	1.388^*** (0.0538)	1.640^*** (0.0955)	1.520^*** (0.0900)
Days of supply = 2, 8-15	1.262^*** (0.0504)	1.539^*** (0.0928)	1.461^*** (0.0895)
Days of supply = 3, 16-27	1.002 (0.0585)	0.997 (0.0957)	0.996 (0.0975)
Constant	0.989 (0.0272)	0.113^*** (0.00513)	0.0500^*** (0.00315)
Controls	No	No	No
Observations	17,158	17,158	17,158

Notes: Data are from the 2011 to 2015 Health Care Cost Institute claims database and capture non-elderly adults initiating buprenorphine treatment. Coefficients are odds ratios based on multivariable logistic regressions. Robust standard errors are in parenthesis.

^***

p<0.01,

^**

p<0.05,

p<0.1.